Literature DB >> 14674212

Aids is now the commonest clinical condition associated with multilineage blood cytopenia in a central referral hospital in Zimbabwe.

E Malyangu1, E A Abayomi, J Adewuyi, A M Coutts.   

Abstract

OBJECTIVE: To describe the clinical features and diagnosis of patients hospitalised and found to have multilineage peripheral blood cytopenias.
DESIGN: Prospective cross sectional study.
SETTING: Parirenyatwa Hospital, a central referral hospital in Harare, Zimbabwe.
SUBJECTS: 231 consecutive patients whose blood parameters revealed bi- or trilinneage cytopenia during a five month period in 1996. MAIN OUTCOME MEASURES: 1. Blood cytopenia was described as: (a) Haemoglobin concentration = or < 100 g/L (b) Total leucocyte count = or < 3.5 x 10(9)/L (c) Platelet count = or < 100 x 10(9)/L 2. Other clinical and diagnostic features.
RESULTS: The highest percentage of multilineage blood cytopenia was in the age bracket 30 to 44 years and the male to female ratio was 1.4:1. Pancytopenia was found in 32.5% of patients, while bilineage cytopenia occurred in 67.5%. The commonest bilineage pattern was the combination of anaemia and thrombocytopenia occurring in 46.3% of all study cases or 68.5% of bilineage cytopenias. Anaemia was the most frequent cytopenia; it was found in 95.2% of all study cases.
CONCLUSION: The commonest condition with which multilineage blood cytopenia was associated was AIDS which was diagnosed in 25.1% of the study cases.

Entities:  

Mesh:

Year:  2000        PMID: 14674212     DOI: 10.4314/cajm.v46i3.8525

Source DB:  PubMed          Journal:  Cent Afr J Med        ISSN: 0008-9176


  2 in total

1.  HIV infection masquerading as idiopathic thrombocytopenic purpura.

Authors:  Sanjay Verma; Piyush Gupta
Journal:  Indian J Pediatr       Date:  2008-01       Impact factor: 1.967

2.  Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection.

Authors:  Amy F Gill; Muhammad H Ahsan; Andrew A Lackner; Ronald S Veazey
Journal:  J Med Primatol       Date:  2012-06       Impact factor: 0.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.